FIELD: biotechnology, in particular epithelial cell growth factors useful in production of new keratinocyte growth factor (KGF).
SUBSTANCE: KGF protein is obtained by cultivation of recombinant host cell, transformed with vector containing DNA which encodes amini acid sequence of KGF protein. Obtained KGF protein in pharmaceutical composition is used for forcing of epithelial cell proliferation. Method of present invention makes it possible to produce KGF protein with specific mitogenic activity of 3.4 x 104 U/mg of protein in relation to keratinocyte cells.
EFFECT: new keratinocyte growth factor.
52 cl, 14 dwg, 3 tbl
| Title |
Year |
Author |
Number |
| ANALOG OF KERATINOCYTE GROWTH NATURAL FACTOR (VERSIONS), PHARMACEUTICAL COMPOSITION, ANALOG-ENCODING RECOMBINANT MOLECULE OF NUCLEIC ACID, EXPRESSION VECTOR, ESCHERICHIA COLI STRAIN TRANSFORMED BY VECTOR, METHOD OF ANALOG PREPARING AND METHOD OF STIMULATION OF FORMATION OF NONFIBROBLASTIC EPITHELIAL CELLS |
1995 |
- Morris Charl'Z F.
- Kennej Uil'Jam S.
- Chen Bao-Lu
- Khsu Ehrik V.
|
RU2198180C2 |
| AGENTS AND METHOD FOR PREPARING HEMOPOIETIC PROTEIN |
1994 |
- Kholli Richard D.
- Lok Si
- Foster Donal'D K.
- Khejgen Frederik S.
- Koshanski Kennet
- Kujdzhper Dzhozef L.
- Lofton-Dej Katerin Eh.
- Oort Piter Dzh.
- Behrkkhed Stiven K.
|
RU2233881C2 |
| ANTIBODY, STOPPING OR RETARDING TUMOUR GROWTH (VERSIONS), METHOD OF SUPPRESSING TUMOUR GROWTH, METHOD OF DIAGNOSING MALIGNANT LESIONS |
2011 |
- Timofeev Il'Ja Valer'Evich
|
RU2440142C1 |
| NOVEL PROTEINS AND METHODS OF THEIR PREPARING |
1996 |
- Goto Masaaki
- Tsuda Ehjsuke
- Motizuki Siniti
- Jano Kazuki
- Kobajasi Fumie
- Sima Nobujuki
- Jasuda Khisataka
- Nakagava Nobuaki
- Morinaga Tomonori
- Ueda Masatsugu
- Khigasio Kandzi
|
RU2194714C2 |
| POLYPEPTIDE-LIGAND FLT3 (VARIANTS), POLYNUCLEOTIDE (VARIANTS), EXPRESSING VECTOR (VARIANTS), STRAIN OF CELL CHO (VARIANTS), METHOD FOR PRODUCING POLYPEPTIDE-LIGAND FLT3 (VARIANTS), PHARMACEUTICAL COMPOSITION (VARIANTS) |
1994 |
- Lajmehn Stjuart D.
- Bekmann M. Patritsija
|
RU2220979C2 |
| INTERFERON-LIKE PROTEIN ZCYTO21 |
2001 |
- Sheppard Pol O.
- Presnell Skott R.
- Foks Brajan A.
- Gilbert Tereza
- Kholdmen Betti A.
- Grant Frehnsis Dzh.
|
RU2292394C2 |
| PROTEIN ABLE TO INHIBIT OSTEOCLASTOGENESIS (OCIF) (VARIANTS), CDNA, METHOD FOR PREPARING PROTEIN, METHOD FOR TREATMENT OF OSTEOPOROSIS, METHOD FOR TREATMENT AND/OR IMPROVEMENT OF BONE MASS RECOVERY, METHOD FOR TREATMENT OF INJURE ASSOCIATED WITH OSSEOUS METABOLISM, TRANSFORMED STRAIN ESCHERICHIA COLI PBK/01F10 AND PHARMACEUTICAL COMPOSITION |
1996 |
- Goto Masaaki
- Tsuda Ehjsuke
- Motizuki Siniti
- Jano Kazuki
- Kobajasi Fumie
- Sima Nobujuki
- Jasuda Khisataka
- Nakagava Nobuaki
- Morinaga Tomonori
- Ueda Masatsugu
- Khigasio Kandzi
|
RU2238948C2 |
| ENHANCEMENT OF IMMUNE RESPONSE WHEREIN FUSED PROTEIN ANTIBODY-CYTOKINE IS MEDIATOR BY COMBINED TREATMENT WITH AGENTS INCREASING IMMUNOCYTOKINE ABSORPTION |
2001 |
- Gilliz Stiven D.
- Lan' Jan'
- Kholden Sil'Vija A.
|
RU2272644C2 |
| FUSED PROTEINS CONTAINING PDGF AND VEGF BINDING PARTS, AND METHODS FOR USE THEREOF |
2014 |
- Pechan Piter
- Ardinger Dzheffri
- Rubin Khillard
- Uodsvort Semyuel
- Skaria Abrakham
|
RU2692652C2 |
| METHOD OF HUMAN ENDOTHELIUM MITOGENIC PROTEIN EXPRESSION IN ESHERICHIA COLI |
0 |
- Majkl Dzhej
- Vilson Berdzhess
- Tomas Mejsiag
- Villyam Drokhan
|
SU1804480A3 |
